Lataa...
MON-361 Isolated ACTH Deficiency after Treatment with Immune-Checkpoint Inhibitors
Background: Immune-checkpoint inhibitors targeting PDI or CTLA-4 are promising therapies in metastatic malignancies, including metastatic melanoma, and their usage has been increasing over the last few years. As more patients are treated with these agents, there will likely be an increased incidence...
Tallennettuna:
| Julkaisussa: | J Endocr Soc |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Endocrine Society
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6550779/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-MON-361 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|